Clinical trial · Observational
CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer
NCT02764606CI-TRIAL-00037893CANPOSunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
CANPOS is a non-interventional study aiming at evaluate at the time of initial surgery the value of new serum markers to predict the occurrence of metastases in patients with early-stage non-small cell lung cancer. This would represent a rational to develop personalized follow-up and prevention strategies
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Serum and plasma samples | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with a non-small cell lung cancer
- description
- Serum and plasma samples (at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases).
- interventionNames
- Biological: Serum and plasma samples
Primary outcomes (1)
- measure
- The Serum levels of osteoprotegerin
- timeFrame
- At the time of initial surgery
- description
- The serum levels of osteoprotegerin, as assessed by standard ELISA methods, will be measured to to evaluate at the time of initial surgery, the value of new serum markers to predict the occurrence of metastases in patients with early-stage non-small cell lung cancer.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * patients with a diagnosis or suspected for a diagnosis of lung cancer, non-small cell lung cancer * age over 18 years * patient naïve of any oncology treatment (excluding surgery alone) within the past 5 years * patient who signed the informed consent by the study protocol Exclusion criteria were: * any ongoing treatment for cancer * any history of cancer within 5 years before the diagnosis of lung cancer * any psychological, sociological or geographical conditions that would not allow the study follow-up
References
Publications (0)
Data not yet available
No reference posted for this study.